MoneyWorks4Me

Ind-Swift Laboratories informs about interest payment

22 Jun 2023 Evaluate
Pursuant to Regulation 57 (4) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Ind-Swift Laboratories has informed about details of interest obligations in respect of the Non-Convertible Debentures of the Company, which are due to be paid during the quarter ending 30th September, 2023-Q2 F/Y 2023-24.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..